Nanotechnology may offer new treatment options for patients suffering from Parkinson's disease or post
In this study, nanotechnology was investigated as a method for delivering drugs through the blood-brain barrier, abbreviated as BBB. The BBB is semi-permeable and protects the brain. Larger molecules cannot pass through the BBB, which poses a limitation when creating medication. For example, dopamine, the neurotransmitter that Parkinson's disease patients are lacking, is too large to pass through the BBB. L-DOPA, the smaller precursor of dopamine, is administered instead. Nanotechnology can deliver certain molecules directly to the central nervous system (CNS), which increases medication options.